Evopoint Biosciences
Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences
Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011
Actionable Insights Powered by AI
Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011